Core Insights - LIXTE Biotechnology Holdings has received a Notice of Allowance for a patent related to combining its LB-100 compound with various cancer immunotherapies, enhancing its intellectual property portfolio [1][2][5] - The company is conducting clinical trials for LB-100 in combination with immunotherapies at notable institutions, including the Netherlands Cancer Institute and MD Anderson Cancer Center [3][4] - LIXTE's LB-100 is positioned as a first-in-class PP2A inhibitor, which is being tested for its potential to improve cancer treatment outcomes [6][7] Patent and Intellectual Property - The newly awarded patent supports LIXTE's commitment to innovative cancer research and treatment solutions [2] - An exclusive patent license agreement with the National Institute of Neurological Disorders and Stroke and the National Cancer Institute allows LIXTE to explore novel combination therapies [5] Clinical Trials and Research - LB-100 is being tested in combination with Roche's atezolizumab for metastatic colon cancer and GSK's dostarlimab-gxly for ovarian clear cell carcinoma [4] - The company is advancing a new treatment paradigm in cancer biology known as activation lethality, with ongoing proof-of-concept trials for various cancer types [7]
LIXTE Receives U.S. Patent Issue Notification for Immune Oncology